The Top Cardiology Trials of 2023

The Bob Harrington Show

For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit:

https://www.medscape.com/author/bob-harrington

ACC 2023 Top Trials

- Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients: CLEAR Outcomes https://www.medscape.com/viewarticle/989100

- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

- Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018

ACC/WCC 2023 Collection Page https://www.medscape.com/viewcollection/36966

ESC 2023 Top Trials

- Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844

- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2306963

- Acoramidis Shows Encouraging Results in ATTR Cardiomyopathy https://www.medscape.com/viewarticle/995883

ESC 2023 Collection Page https://www.medscape.com/viewcollection/36988

AHA 2023 Top Trials

- Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT https://www.medscape.com/viewarticle/998373

- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

- Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.18949

- Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2 https://www.medscape.com/s/viewarticle/998375

- A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina https://www.nejm.org/doi/full/10.1056/NEJMoa2310610

- Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA https://www.medscape.com/viewarticle/998418

- Promising First Results With DNA Editing to Lower LDL https://www.medscape.com/s/viewarticle/998719

- Single Injection Reduces Blood Pressure for 6 Months: KARDIA-1 https://www.medscape.com/viewarticle/998666

AHA 2023 Collection Page https://www.medscape.com/viewcollection/37277

Other Mentions

- N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173

- Rimonabant: From RIO to Ban https://doi.org/10.1155%2F2011%2F432607

- Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial https://doi.org/10.1016/S0140-6736(17)32714-9

- Asundexian Phase 3 AF Study Halted for Lack of Efficacy https://www.medscape.com/viewarticle/998665

- Challenges in the Design and Interpretation of Noninferiority Trials https://www.nejm.org/doi/full/10.1056/nejmra1510063

- Milvexian for the Prevention of Venous Thromboembolism https://www.nejm.org/doi/full/10.1056/NEJMoa2113194

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact [e-mail]